Shareholders Support Management Proposals At SYGNIS’ AGM With Overwhelming Majority
7/21/2014 8:58:11 AM
Madrid, Spain and Heidelberg, Germany, 21 July 2014 - At the Annual General Meeting
(AGM) of SYGNIS AG (Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard) held on
17 July 2014 shareholders representing 83 percent of the capital approved all proposals of
the Management with an overwhelming majority. Main decisions were related to the
discharge of the members of the Supervisory and the Management Board for the past
Fiscal Year, the election of new members of the Supervisory Board, as well as the creation
of new authorised capital.
Mr. Werner-Friedrich Knuth Schaefer has left the Supervisory Board. Dr. Cristina
Garmendia Mendizábal, Chairwoman of the Supervisory Board thanked Mr. Werner-
Friedrich Knuth Schaefer for his work and efforts for SYGNIS AG. She welcomed Mrs.
Maria Jesús Sabatés Mas as new member of the Supervisory Board.
At the Annual General Meeting, Pilar de la Huerta, CEO and CFO of SYGNIS, highlighted
the strategic and financial achievements during fiscal year 2013 including the completion
of the restructuring measures, the launch of the first products based on SYGNIS’
proprietary technology QualiPhi® (now renamed SensiPhi®) by QIAGEN and the very
successful capital increase. For the current year, Mrs. de la Huerta expects the
development of further products in the field of DNA amplification and sequencing and the
strengthening of SYGNIS’ position especially in the market for Next Generation
You will find further information about our AGM and the detailed voting results on our
website: www.sygnis.com in the Investor Relations section.
For further information please contact:
Pilar de la Huerta
Tel: +34 91 192 36 50
About SYGNIS AG: www.sygnis.com
After the merger in 2012 between X-Pol Biotech, specializing in DNA amplification and
sequencing, and SYGNIS AG, listed in the German Stock Exchange (Prime Standard
segment, Tick: LIO1; ISIN: DE000A1RFM03), SYGNIS’ new mission is to develop and
distribute technologies and products from X-Pol, which has a commercial product in the
DNA amplification segment, SensiPhi® and is currently developing other products in the
field of Next Generation Sequencing.
Help employers find you! Check out all the jobs and post your resume.
comments powered by